American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.

[1]  K. Price,et al.  Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. , 2007, Allergy and asthma proceedings.

[2]  M. Castells.  Desensitization for drug allergy , 2006, Current opinion in allergy and clinical immunology.

[3]  A. Parker,et al.  Rates of retrieval of self-injectable epinephrine prescriptions: a descriptive report. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  J. Klastersky.  Adverse effects of the humanized antibodies used as cancer therapeutics , 2006, Current opinion in oncology.

[5]  T. Yamaji,et al.  PS80 interferes with the antiallergic effect of Cry‐consensus peptide, a novel recombinant peptide for immunotherapy of Japanese cedar pollinosis, at very low concentration through modulation of Th1/Th2 balance , 2006, Immunology.

[6]  F. Simons,et al.  Anaphylaxis, killer allergy: long-term management in the community. , 2006, The Journal of allergy and clinical immunology.

[7]  D. Hepner,et al.  Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. , 2006, The Journal of allergy and clinical immunology.

[8]  L. Mayer,et al.  Monoclonal antibodies, immunogenicity, and associated infusion reactions. , 2005, The Mount Sinai journal of medicine, New York.

[9]  R. Steele,et al.  Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin (Case Report) , 2005, Nephrology.

[10]  D. Hepner,et al.  Symposium on the definition and management of anaphylaxis: summary report. , 2005, The Journal of allergy and clinical immunology.

[11]  E. Haddad,et al.  Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab , 2003, Transplantation.

[12]  S. Plevy,et al.  The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.

[13]  K. Woodside,et al.  Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody , 2002, Transplantation.

[14]  R. Nicklas.  The diagnosis and management of anaphylaxis , 2005 .